AB Science says a newly identified blood biomarker may help assess masitinib activity in its ongoing Phase 3 ALS clinical trial.
Blood lactate levels were associated with survival and weight changes in ALS, according to a study in Australia and Japan.
In this episode of Denatured, you'll be listening to Indu Navar, CEO and founder of EverythingALS and Dr. Olga Uspenskaya, ...
PRESS RELEASE AB SCIENCE ANNOUNCES THE IDENTIFICATION OF A PLASMA BIOMARKER THAT INDICATES THE ACTIVITY OF MASITINIB IN TREATING AMYOTROPHIC LATERAL SCLEROSIS, AND THAT IS CAPABLE OF IDENTIFYING ...
SALT LAKE CITY, Dec. 03, 2025 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene” or the “Company”) and its wholly owned subsidiary Clene Nanomedicine, Inc., a late ...
Researchers have revealed that blood lactate is a key biomarker that can predict physical outcomes and prognosis in patients ...
Clene (NASDAQ:CLNN) executives used a conference presentation to outline near-term regulatory plans for CNM-Au8 in ...
Tania Gendron, PhD, speaks to the present challenges for translating biomarker discoveries to clinical practice and offers insights to how these can be overcome. Biomarker exploration has been a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results